skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: p53-dependent and p53-independent anticancer activity of a new indole derivative in human osteosarcoma cells

Journal Article · · Biochemical and Biophysical Research Communications
 [1];  [2];  [3];  [4]; ; ;  [2];  [5];  [2];  [2];  [4];  [2]
  1. Department for Life Quality Studies, University of Bologna, Rimini Campus, Rimini (Italy)
  2. Department of Pharmacy and Biotechnology, University of Bologna, Bologna (Italy)
  3. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna (Italy)
  4. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna (Italy)
  5. ELETTRA–Sincrotrone Trieste S.C.p.A., Trieste (Italy)

Osteosarcoma (OS) is the most common primary malignant tumor of bone, occurring most frequently in children and adolescents. The mechanism of formation and development of OS have been studied for a long time. Tumor suppressor pathway governed by p53 gene are known to be involved in the pathogenesis of osteosarcoma. Moreover, loss of wild-type p53 activity is thought to be a major predictor of failure to respond to chemotherapy in various human cancers. In previous studies, we described the activity of a new indole derivative, NSC743420, belonging to the tubulin inhibitors family, capable to induce apoptosis and arrest of the cell cycle in the G2/M phase of various cancer cell lines. However, this molecule has never been tested on OS cell line. Here we address the activity of NSC743420 by examine whether differences in the p53 status could influence its effects on cell proliferation and death of OS cells. In particular, we compared the effect of the tested molecule on p53-wild type and p53-silenced U2OS cells, and on SaOS2 cell line, which is null for p53. Our results demonstrated that NSC743420 reduces OS cell proliferation by p53-dependent and p53-independent mechanisms. In particular, the molecule induces proliferative arrest that culminate to apoptosis in SaOS2 p53-null cells, while it brings a cytostatic and differentiating effect in U2OS cells, characterized by the cell cycle arrest in G0/G1 phase and increased alkaline phosphatase activity. - Highlights: • The indole derivative NSC743420 induces antitumor effects on osteosarcoma cells. • p53 status could drive the activity of antitumor agents on osteosarcoma cells. • NSC743420 induces cytostatic and differentiating effects on U2OS cells. • NSC743420 causes apoptosis on p53-null SaOS2 cells.

OSTI ID:
22592802
Journal Information:
Biochemical and Biophysical Research Communications, Vol. 467, Issue 2; Other Information: Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
Country of Publication:
United States
Language:
English